Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	62.43	61.3	383.22	128.03	393.64	595.08
Short-Term Investments	214.16	233.28	98.96	128.52	-	-
Cash & Short-Term Investments	276.59	294.58	482.18	256.55	393.64	595.08
Cash Growth	-2.78%	-38.91%	87.95%	-34.83%	-33.85%	8134.15%
Other Receivables	62.46	60.34	45.58	39.15	26.72	16.81
Receivables	62.46	60.34	45.58	39.15	26.72	16.81
Prepaid Expenses	0.36	0.77	0.84	1.65	2.79	4.66
Other Current Assets	9.27	12.18	7.81	17.74	14.59	12.22
Total Current Assets	348.68	367.88	536.41	315.09	437.75	628.77
Property, Plant & Equipment	10.52	10.85	11.76	12.95	1.17	0.16
Long-Term Investments	257.12	282.55	-	-	-	-
Long-Term Deferred Tax Assets	24.17	24.78	26.59	29.65	3.51	-
Other Long-Term Assets	1.28	1.44	2.05	2.55	1.88	0.7
Total Assets	641.76	687.5	576.8	360.25	444.31	629.64

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	10.66	7.58	7.14	11.82	13.84	8.07
Accrued Expenses	24.93	34.42	49.31	26.62	22.23	15.7
Current Portion of Leases	0.74	0.71	0.6	-	-	-
Current Income Taxes Payable	-	-	0.84	0.11	1.58	0.77
Other Current Liabilities	0.24	0.22	0.11	0.84	0.69	0.1
Total Current Liabilities	36.57	42.94	58	39.39	38.34	24.64
Long-Term Debt	110.44	110.1	108.94	75.7	69.8	75.7
Long-Term Leases	7.37	7.57	8.29	8.89	-	-
Other Long-Term Liabilities	0.03	0.03	0.03	0.03	-	37.74
Total Liabilities	154.42	160.63	175.25	124	108.14	138.08

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.42	0.41	0.36	0.27	0.27	0.25
Additional Paid-In Capital	1,751	1,710	1,386	987.42	939.26	876.27
Retained Earnings	-1,265	-1,186	-988.7	-752.95	-601.86	-385.65
Comprehensive Income & Other	1.41	2.71	4.21	1.49	-1.5	0.69
Shareholders' Equity	487.35	526.86	401.55	236.24	336.17	491.55
Total Liabilities & Equity	641.76	687.5	576.8	360.25	444.31	629.64

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	118.56	118.38	117.83	84.59	69.8	75.7
Net Cash (Debt)	158.03	176.2	364.35	171.96	323.84	519.38
Net Cash Growth	-5.09%	-51.64%	111.88%	-46.90%	-37.65%	32361.38%
Net Cash Per Share	1.12	1.30	3.18	1.79	3.47	6.91
Filing Date Shares Outstanding	154.73	154.57	133.18	100.31	94.96	94.02
Total Common Shares Outstanding	154.73	149.23	132.63	98.77	94.84	89.99
Working Capital	312.11	324.94	478.41	275.71	399.41	604.14
Book Value Per Share	3.15	3.53	3.03	2.39	3.54	5.46
Tangible Book Value	487.35	526.86	401.55	236.24	336.17	491.55
Tangible Book Value Per Share	3.15	3.53	3.03	2.39	3.54	5.46
Machinery	1.91	1.91	1.54	1.5	0.44	0.2
Construction In Progress	-	-	-	-	0.89	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error